Double-blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases;Essai comparatif randomisé en double aveugle clodronate oral 1600 mg/j versus placebo chez des patientes avec métastases osseuses de cancer du sein

Bulletin du Cancer

Volumn 88, Issue 7, 2001, Pages 701-707

  Tubiana Hulin, M ^a   Beuzeboc, P ^a   Mauriac, L ^a   Barbet, N ^a   Frenay, M ^a   Monnier, A ^a   Pion, J M ^a   Switsers, O ^a   Misset, J L ^a   Assadourian, S ^a   Bessa, E ^a  

^a CENTRE RENÉ HUGUENIN   (France)

Author keywords

Bisphosphonate; Bone metastasis; Breast cancer; Clodronate; Malignant osteolysis; Placebo

Indexed keywords

ANALGESIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; PLACEBO;

ADULT; AGED; ARTICLE; BONE METASTASIS; BREAST CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG WITHDRAWAL; EDEMA; FATIGUE; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; HYPERCALCEMIA; MAJOR CLINICAL STUDY; OSTEOLYSIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VOMITING;

ADMINISTRATION, ORAL; ADULT; AGED; ANALGESICS, NON-NARCOTIC; ANTINEOPLASTIC AGENTS; BONE DISEASES; BONE NEOPLASMS; BREAST NEOPLASMS; CLODRONIC ACID; DOUBLE-BLIND METHOD; FEMALE; HORMONES; HUMANS; MIDDLE AGED; PAIN; PAIN MEASUREMENT;

EID: 17444435152     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Bone metastases in breast cancer patients
2. Management of breast cancer with bone metastases
3. Metastatic breast cancer: Clinical course, prognosis and therapy related to the first site of metastatis
4. An evaluation of the potential cost reductions resulting from the use of clodronate in the treatment of metastatic carcinoma of the breast to bone
5. Mechanisms of bone metastases
6. Cellular and molecular mechanisms of breast and prostate cancer metastasis to bone
7. Localization of parathyroid hormone-related protein mRNA expression in breast cancer and metastatic lesions by in situ hybridation
8. Rôle des ostéoclastes dans les mécanismes physiopathologiques de l'ostéolyse maligne
9. The distribution of secondary growths in cancer of the breast
10. Biphosphonates
11. Current use of bisphosphonates in oncology
12. Clodronate: A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease
13. Reduction in new metastases in breast cancer with adjuvant clodronate treatment
14. Antitumour effects of bisphosphonates: First evidence and possible mechanisms of action
15. Bisphosphonates in the adjuvant treatment of cancer: Experimental evidence and first clinical results
16. Mécanismes d'action des bisphosphonates sur les cellules tumorales et perspectives d'utilisation dans l'ostéolyse maligne
17. Molecular mechanisms of action of bisphosphonates
18. Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices
19. Double blind placebo controlled trial of oral clodronate in patients with bone metastases: Effect on induced osteolysis
20. Clinical course of breast cancer patients with osseous metastasis treated with combination chemotherapy
21. Risk of complications from bone metastases in breast cancer: Implication for management
22. Steroid hormone receptor activity of primary human breast cancer and pattern of first metastasis
23. Clinical course and prognosis factors following bone recurrence from breast cancer
24. Bone secondaries in breast cancer: The solitary metastasis
25. Stage IV breast cancer: Clinical course and survival of patients with osseous versus extraosseous metastases at initial diagnosis
26. Metastatic breast cancer confined to the skeletal system: An indolent disease
27. Use of bisphosphonates in cancer patients
28. Bisphosphonates et métastases osseuses
29. Overview of bisphosphonates
30. Should bisphosphonates be part of the standard therapy of patients with multiple myeloma or bone metastases from other cancers? An evidence-based review
31. The clinical history of bone metastases in breast cancer
32. Double blind controlled trial of oral clodronate in patients with bone metastases from breast cancer
33. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases Protocol 19 Aredia Breast Cancer
34. Long term prevention of skeletal complications of metastatic breast cancer with pamidronate
35. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases
36. Oral clodronate in breast cancer patients with bone metastases: A randomized study
37. Presenting features and subsequent skeletal events in metastatic breast cancer
38. American Society of Clinical Oncology Guideline on the role of bisphosphonates in breast cancer
39. Osteoporosis due to cancer treatment: Pathogenesis and management
40. Effet placebo sur les douleurs méastatiques osseuses
41. The role of biphosphonates in the treatment of painful metastatic bone disease: A review of phase III trials
42. Should bisphosphonates be standard therapy for bone pain?
43. Bisphosphonates for metastatic bone pain
44. Pain control in patients with cancer